Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy

• Status: Unknown status
• Trial end date: 2016-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the short-term effect of intravitreal aflibercept injection between two subtypes of polypoidal choroidal vasculopathy

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yeungnam University College of Medicine
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

1. symptomatic typical PCV accompanying branch vascular network involving subfoveal area

2. signed informed consent; and

3. over 6 months follow-up period after enrollment.

Exclusion Criteria:

1. retinal diseases other than PCV

2. extrafoveal PCV not involving subfoveal area

3. massive subretinal hemorrhage blocking polypoidal lesion on ICGA

4. severe media opacity such as senile cataract

5. previous history of intravitreal injection

6. previous intraocular surgery history except cataract surgery which was done more than 3 months.